Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437160 | 1.00 | CTSL (0.60) | CTSLACEGAARAB9AMAPT | |
| SCHEMBL27172205 | 0.96 | CTSL (0.57) | CTSLACEGAARAB9AMAPT | |
| SCHEMBL20838261 | 0.83 | CTSL (0.71) | CTSLACEGAARAB9AALDH1A1 | |
| SCHEMBL19437162 | 0.83 | CTSL (0.71) | CTSLACEGAARAB9AALDH1A1 | |
| SCHEMBL19485398 | 0.81 | MAPT (0.59) | CTSLGAARAB9AMAPTTDP1 | |
| SCHEMBL27616693 | 0.81 | CTSL (0.60) | CTSLACEGAARAB9AMAPT | |
| SCHEMBL28716640 | 0.81 | CTSL (0.55) | CTSLACEGAARAB9AMAPT | |
| SCHEMBL9237730 | 0.81 | RAB9A (0.61) | CTSLGAARAB9AMAPTTDP1 | |
| SCHEMBL9237734 | 0.81 | RAB9A (0.61) | CTSLGAARAB9AMAPTTDP1 | |
| SCHEMBL1324941 | 0.81 | CTSS (0.59) | CTSLACECTSSCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440051-B1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | RES TRIANGLE INST (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | RESEARCH TRIANGLE INSTITUTE (US) | 2021-10-12 | — | — | US | disclosed |
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092809-A1 | NEUROPEPTIDE S RECEPTOR (NPSR) AGONISTS | NPSR1, GRPR, NPBWR1 | CTSL 252/4885ACE 1441/4885GAA 671/4885 |
| US-11142546-B2 | Neuropeptide S receptor (NPSR) agonists | NPSR1, GRPR, NPBWR1 | CTSL 252/4885ACE 1441/4885GAA 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.